Observational studyMedicine2025
HALP score and GNRI: Simple and powerful prognostic markers in diffuse large B-cell lymphoma.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- The Prognostic Significance of the Systemic Inflammation Response Index (SIRI) and HALP Score in Hodgkin's Lymphoma.Diagnostics (Basel, Switzerland) · 2026Article
- Prognostic value of BMI, prognostic nutritional index, and CRP in patients with lymphoma after autologous hematopoietic stem cell transplantation.Biomedical engineering online · 2026Article
- Low serum albumin levels and the nongerminal center B-cell subtype according to the Hans algorithm as strong prognostic factors in ≥ 80-year-old patients with large B-cell lymphoma treated with rituximab-containing chemotherapy.Annals of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. It is a heterogeneous group of diseases that may need very aggressive treatment in some cases. Prognostic evaluation is very important in determining the best treatment. However, in some clinics, access to genetically based and expensive diagnostic methods is limited. In this study, we analyzed the prognostic value of Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score and Geriatric Nutritional Risk Index (GNRI) in DLBCL patients. 201 Patients with newly diagnosed DLBLC between 2005 and 2022 were retrospectively evaluated. Optimal cutoff points for the HALP score and the GNRI were calculated with the receiver operating characteristic curve analysis. Kaplan-Meier method was used to compare survival and disease-free survival times between HALP score groups. In the receiver operating characteristic curve analysis, the cutoff points were found 26.17 for HALP, and 99.17 for GNRI. Groups with lower HALP scores and lower GNRIs had significantly shorter overall survival and disease-free survival. Univariate analyses showed that lower HALP score, lower GNRI and higher lactic dehydrogenase, Ann-Arbor stage, International Prognostic Index (IPI), National Comprehensive Cancer Network-IPI and Revised-IPI scores were associated with worse survival rates (P < .05). According to the results of the multivariate Cox regression model, patients with HALP score ≤ 26.17 (OR: 2.32; 95%CI: 1.31-4.11 P = .004) increased the risk of death (P = .001, -2 loglikelihood = 506.15). Similarly, a GNRI score ≤ 99.17 was significantly correlated with worse survival outcomes (P < .001). HALP score and GNRI score are reliable, simple and easily accessible indices that can be used to predict the prognosis of DLBLC patients. DLBLC patients with low HALP score and low GNRI level may be associated with short survival and early nutritional support should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.